

Table S1: Detailed vaccine recipients from all vaccination sites

Site	Date	Vaccine recipients (N)	Agreed to participate (N)	Complete follow-up (N)
Laksi-1	31 Jul 21 to 1 Aug 21	3066	2938	2720
Laksi-2	8 Sep 21 to 10 Sep 21	2993	2902	2621
Don Mueang	13 Sep 21 to 14 Sep 21	2920	2548	2465
Saimai	16 Sep 21 to 18 Sep 21	3084	2902	2742
Total		12063	11290	10548

Table S2: Specific diseases and medications currently used in participants with autoimmune disease (N=68)

Disease/ Medications currently used	Number of participants (%)
Rheumatic autoimmune disease	56 (82.4%)
- Use steroid only	6 (8.8%)
- Use immunosuppressants only	13 (19.1%)
- Use steroid + immunosuppressants	20 (29.4%)
- No steroid & immunosuppressant	17 (25.0%)
Non-rheumatic autoimmune disease	12 (17.6%)
- Use steroid only	3 (4.4%)
- Use immunosuppressants only	8 (11.8%)
- Use steroid + immunosuppressants	0 (0%)
- No steroid & immunosuppressant	1 (1.5%)
Total number of participants	68 (100%)

Table S3: Baseline characteristic of participants who lost to follow-up (N=742), compared with participants including in the study (N = 10 548)

	Participants who were dropped out (N=742)	Participants who were included in the study (N= 10 548)	P-value
Gender			
• Male	388 (52.29%)	4767 (45.19%)	<0.001
• Female	354 (47.71%)	5781 (54.81%)	
Median age (IQR); year	40 (26 – 54)	41 (29-52)	0.39
BMI; Mean±SD.; kg/m ²	24.43 ± 4.62	24.49 ± 4.92	0.75
Any Comorbidities	161 (21.70%)	2143 (20.32%)	0.36
Diabetes mellitus	54 (7.28%)	645 (6.11%)	0.20
Hypertension	114 (15.36%)	1432 (13.58%)	0.17
Chronic lung disease	12 (1.62%)	188 (1.78%)	0.74
Cardiac disease	13 (1.75%)	121 (1.15%)	0.14
Stroke	10 (1.35%)	59 (0.56%)	0.008
Chronic kidney disease	4 (0.54%)	36 (0.34%)	0.38
Cancer	9 (1.21%)	58 (0.55%)	0.023
Autoimmune disease	6 (0.81%)	68 (0.64%)	0.59